NASDAQ:CGON • US1569441009
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CG ONCOLOGY INC (CGON).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-27 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-02-10 | Truist Securities | Maintains | Buy -> Buy |
| 2026-01-21 | RBC Capital | Maintains | Outperform -> Outperform |
| 2026-01-16 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2026-01-12 | Truist Securities | Maintains | Buy -> Buy |
| 2025-12-11 | Wedbush | Initiate | Outperform |
| 2025-11-24 | Truist Securities | Initiate | Buy |
| 2025-11-17 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-10-08 | Guggenheim | Initiate | Buy |
| 2025-09-26 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-09-17 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-09-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-09-08 | Jones Trading | Initiate | Buy |
| 2025-09-08 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-09-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-09-05 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-19 | Piper Sandler | Initiate | Overweight |
| 2025-07-16 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-06-17 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-05-19 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-05-02 | JP Morgan | Initiate | Overweight |
| 2025-04-29 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-04-28 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-04-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-04-16 | ScotiaBank | Initiate | Sector Perform |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 204K 6.81% | 1.139M 458.33% | 4.04M 254.70% | 20.521M 407.95% | 135.45M 560.06% | 475.35M 250.94% | 926.18M 94.84% | 1.462B 57.85% | 1.928B 31.87% | 2.211B 14.68% | 2.741B 23.97% | |
| EBITDA YoY % growth | -55.432M -57.34% | -114.634M -106.80% | -189.329M -65.16% | -228.496M -20.69% | -208.602M 8.71% | -180.632M 13.41% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -55.449M -57.32% | -114.666M -106.80% | -190.774M -66.37% | -237.587M -24.54% | -239.4M -0.76% | -34.227M 85.70% | 360.61M 1,153.59% | 773.42M 114.48% | 1.232B 59.29% | 1.399B 13.56% | 1.552B 10.94% | |
| Operating Margin | -27,180.88% | -10,067.25% | -4,722.13% | -1,157.78% | -176.74% | -7.20% | 38.94% | 52.90% | 63.90% | 63.27% | 56.62% | |
| EPS YoY % growth | N/A | -1.42 -4.48% | -2.09 -47.18% | -2.51 -20.30% | -2.11 16.02% | 0.08 104.01% | 2.72 3,110.84% | 5.77 112.29% | 9.04 56.72% | 10.70 18.27% | 11.86 10.90% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.59 -31.05% | -0.63 -17.45% | -0.74 -30.08% | -0.80 -51.33% |
| Revenue Q2Q % growth | 311.61K 499.25% | 204.571K | 291.424K -82.51% | 4.473M 92.64% |
| EBITDA Q2Q % growth | -52.362M -24.14% | -56.683M -16.73% | N/A | N/A |
| EBIT Q2Q % growth | -54.588M -29.34% | -51.788M -6.25% | -55.131M -7.83% | -65.749M -35.01% |
All data in USD
21 analysts have analysed CGON and the average price target is 83.39 USD. This implies a price increase of 29.04% is expected in the next year compared to the current price of 64.62.
CG ONCOLOGY INC (CGON) will report earnings on 2026-05-11.
The consensus EPS estimate for the next earnings of CG ONCOLOGY INC (CGON) is -0.59 USD and the consensus revenue estimate is 311.61K USD.
The consensus rating for CG ONCOLOGY INC (CGON) is 83.8095 / 100 . This indicates that analysts generally have a positive outlook on the stock.